...Thank you, Michelle, and thanks to everyone for joining us today. Ton has made significant progress in the past year across our two gene therapy programs. And while the focus of today's call is on the compelling early data generated from our TN 401 program, we also want to take a moment to share a positive update on TN 201, our gene therapy program for my BPC-3 associated hypertrophic cardiomyopathy or HCM. We are pleased to share that the procedural clinical hold that was placed on the MyPEAK-1 trial of TN 201 has been lifted by the FDA. As you may recall, the hold was instituted following our proactive outreach to the agency to share clinical data from the TN 201 program and to discuss next steps for development. We amended the MyT1 protocol per FDA request to incorporate learnings related to patient monitoring and management of the immune suppression regimen. We were completely aligned with the FDA's suggestions, and after addressing all of their questions and concerns, the hold was...
